EPISODE · May 14, 2025 · 10 MIN
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
from BiotechTV - News · host BiotechTV
CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A first program recently had its IND cleared.
Embed this episode
Ready to play
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
0:00
10:06
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 10 minutes long.
When was this BiotechTV - News episode published?
This episode was published on May 14, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!